---
title: "ABT Earnings: Abbott Stock Sinks as Profit Hit Takes Shine Off Sales Growth"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/273382947.md"
description: "Abbott Laboratories (ABT) shares fell after the company reported fourth-quarter sales growth of $11.46 billion, a 5% increase from the previous year, but below Wall Street's expectation of $11.80 billion. The company's diluted earnings per share dropped to $1.01, an 81% decline from $5.27 a year earlier, missing analysts' expectations of $1.50."
datetime: "2026-01-22T13:43:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273382947.md)
  - [en](https://longbridge.com/en/news/273382947.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273382947.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/273382947.md) | [繁體中文](https://longbridge.com/zh-HK/news/273382947.md)


# ABT Earnings: Abbott Stock Sinks as Profit Hit Takes Shine Off Sales Growth

Abbott Laboratories' (ABT) shares came down with a fever early Thursday after the American healthcare company posted sales growth for its fourth quarter, but saw a dip in its profit. Its earnings also fell short of Wall Street's expectations.

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

In the last three months of 2025, the Illinois-based company, which manufactures drugs, medical devices, diagnostic equipment, and nutritional products, generated $11.46 billion in sales. This is roughly a 5% rise from $10.97 billion seen a year ago, but is below the Wall Street consensus of $11.80 billion.

In addition, the firm reported diluted earnings per share of $1.01, which marks an 81% drop from $5.27 a year earlier and missed analysts' expectations of $1.50.

### Related Stocks

- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)
- [SPDR® S&P Health Care Equipment ETF (XHE.US)](https://longbridge.com/en/quote/XHE.US.md)
- [Abbott Laboratories (ABT.US)](https://longbridge.com/en/quote/ABT.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [iShares US Medical Devices ETF (IHI.US)](https://longbridge.com/en/quote/IHI.US.md)

## Related News & Research

- [What Abbott Laboratories (ABT)'s Oncology Test Integration Into OncoEMR Means For Shareholders](https://longbridge.com/en/news/281606975.md)
- [Net Worth Advisory Group Acquires Shares of 10,905 Abbott Laboratories $ABT](https://longbridge.com/en/news/280874003.md)
- [Major Investor Quietly Ramps Up Stake in Vivos Therapeutics](https://longbridge.com/en/news/281596321.md)
- [Michael C. Skaff Discloses Investment at Vivos Therapeutics with 19.9% Stake](https://longbridge.com/en/news/281582214.md)
- [2 Defensive Healthcare Stocks to Buy Right Now](https://longbridge.com/en/news/280043392.md)